摘要
目的探讨奥氮平联合齐拉西酮治疗老年重性精神分裂症临床疗效以及对患者血清神经生长因子、胶质纤维酸性蛋白因子表达的影响.方法将82例老年重性精神分裂症患者按治疗方案不同分为研究组和对照组各41例,两组均口服奥氮平治疗,研究组在此基础上联合齐拉西酮治疗,观察2个月.于治疗前后采用阳性与阴性症状量表评定临床疗效,简易精神状态量表评定精神状态,个人和社会功能量表评定社会功能,不良反应量表评定不良反应;治疗前后检测两组血清神经生长因子、胶质纤维酸性蛋白因子水平变化.结果(1)治疗2个月研究组总有效率(92.7%)显著高于对照组(75.6%)(P<0.05).(2)治疗后两组简易精神状态量表与个人和社会功能量表评分均较治疗前显著升高(P <0.01),研究组评分均显著高于对照组(P <0.01).(3)治疗后两组血清神经生长因子水平较治疗前显著升高,研究组显著高于对照组(P<0.01),两组血清胶质纤维酸性蛋白因子水平较治疗前显著下降,研究组显著低于对照组(P<0.01).(4)治疗后两组总体不良反应发生率比较差异无统计学意义(P>0.05).结论奥氮平联合齐拉西酮治疗老年重性精神分裂症患者疗效显著,能显著提高血清神经生长因子表达水平,降低血清胶质纤维酸性蛋白因子水平,有利于改善患者的精神症状和社会功能,安全性高.
Objective To investigate the clinical efficacy of olanzapine combined with ziprasidone in the treatment of elderly patients with severe schizophrenia and its effect on serum NGF, GFAP expression. Methods 82 elderly patients with severe schizophrenia were divided into study group and control group ac-cording to different treatment options, 41 cases in each group. The two groups were treated with oral olanzapine. The study group was treated with ziprasidone on the basis of the control group, patients were observed for 2 months. PANSS was used to evaluate clinical efficacy before and after treatment, MMSE assessed mental status,PSP assessed social function, and adverse reaction scale assessed adverse reac-tions. The levels of NGF and GFAP were measured before and after treatment. Results (1) The total ef-fective rate of the study group (92. 7%) was significantly higher than that of the control group at 2 months after treatment (75.6%)(P<0. 05).(2) After treatment, the MMSE and PSP scores of the two groups were significantly higher than those before treatment (P<0. 01), and the scores of the study group were significantly higher than those the control group (P<0. 01).(3) The levels of NGF in the two groups were significantly higher than those before treatment. The study group was significantly higher than the control group (P<0. 01). The serum GFAP levels in the two groups were significantly lower than those before the treatment, and the study group was significantly lower than the control group (P< 0. 01).(4) There was no significant difference in the incidence of overall adverse reactions between the two groups after treatment (P>0. 05). Conclusions Olanzapine combined with ziprasidone is effective in the treatment of elderly patients with severe schizophrenia. It can significantly increase the expression of ser-um nerve growth factor and decrease the level of serum GFAP, which is beneficial to improve the patients mental symptoms and social functions, and is highly safe.
作者
程群
张秀丽
乔志康
Cheng Qun;Zhang Xiuli;Qiao Zhikang(Jiaozuo City Mental Hospital ,Jiaozuo 454000,Henan,China)
出处
《临床心身疾病杂志》
CAS
2019年第5期39-41,45,共4页
Journal of Clinical Psychosomatic Diseases
作者简介
程群,男,48岁,汉族,本科,副主任医师,院长.主要研究成果:获市级科技成果一等奖1项,发表专业论文10余篇。研究方向:精神疾病诊治及医院管理。
